NDC 0220-9280
Oscillococcinum
Cairina Moschata Heart/liver Autolysate
Oscillococcinum is a Oral Pellet in the Human Otc Drug category. It is labeled and distributed by Laboratoires Boiron. The primary component is Cairina Moschata Heart/liver Autolysate.
| Product ID | 0220-9280_5e33cfd3-5c6b-1a87-e053-2a91aa0ad7a3 |
| NDC | 0220-9280 |
| Product Type | Human Otc Drug |
| Proprietary Name | Oscillococcinum |
| Generic Name | Cairina Moschata Heart/liver Autolysate |
| Dosage Form | Pellet |
| Route of Administration | ORAL |
| Marketing Start Date | 1998-08-01 |
| Marketing Category | UNAPPROVED HOMEOPATHIC / UNAPPROVED HOMEOPATHIC |
| Labeler Name | Laboratoires Boiron |
| Substance Name | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| Active Ingredient Strength | 200 [hp_C]/1 |
| NDC Exclude Flag | N |
| Listing Certified Through | 2020-12-31 |
Packaging
NDC 0220-9280-32
3 TUBE in 1 CARTON (0220-9280-32) > 200 PELLET in 1 TUBE
| Marketing Start Date | 1998-08-01 |
| NDC Exclude Flag | N |
| Sample Package? | N |
NDC SPL Data Element Entries
NDC 0220-9280-33 [00220928033]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
NDC 0220-9280-37 [00220928037]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
| Marketing End Date | 2014-12-31 |
NDC 0220-9280-38 [00220928038]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
| Marketing End Date | 2014-12-31 |
NDC 0220-9280-36 [00220928036]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
NDC 0220-9280-35 [00220928035]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
| Marketing End Date | 2012-12-31 |
NDC 0220-9280-34 [00220928034]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
NDC 0220-9280-32 [00220928032]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
| Marketing End Date | 2012-12-31 |
NDC 0220-9280-31 [00220928031]
Oscillococcinum PELLET
| Marketing Category | unapproved homeopathic |
| Product Type | HUMAN OTC DRUG |
| Marketing Start Date | 1998-08-01 |
| Marketing End Date | 2012-12-31 |
Drug Details
Active Ingredients
| Ingredient | Strength |
|---|---|
| CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE | 200 [hp_C]/1 |
OpenFDA Data
| SPL SET ID: | 11a2f33d-1c66-422e-9ec0-fbb114007080 |
| Manufacturer | |
| UNII |
NDC Crossover Matching brand name "Oscillococcinum" or generic name "Cairina Moschata Heart/liver Autolysate"
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0220-9280 | Oscillococcinum | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 61727-345 | ANACOCCINUM | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 71919-055 | Anas barbariae | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 68428-205 | Anas barbariae, hepatis et cordis extractum | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 11822-2235 | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 63868-306 | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 71753-1054 | Coxiflu | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 42681-9280 | Flu Ease | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 42681-9281 | Flu Ease | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
| 68016-627 | PREMIER VALUE FLU RELIEF | CAIRINA MOSCHATA HEART/LIVER AUTOLYSATE |
Trademark Results [Oscillococcinum]
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
 OSCILLOCOCCINUM 73373300 1305677 Live/Registered |
Fournier; Marie-Louise Henriette 1982-07-06 |
© 2025 FDA.report
This site is not affiliated with or endorsed by the FDA.